Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation
NCT03961256 on ClinicalTrials.gov · last registry update 2022-10-28
A small phase 2 — 9 participants, against a typical 110. The sponsor logged completion for 18 October 2021. Primary outcome, as filed: Progression From Prediabetes to Diabetes. exenatide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Mayo Clinic
- Sponsor type
- Other
- Enrollment
- 9
- Started
- 2019-05-09
- Primary completion
- 2021-10-18 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Progression From Prediabetes to Diabetes
Conditions studied
Pre Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.